Research Paper Volume 11, Issue 19 pp 8681—8700

The prognostic value of YAP1 on clinical outcomes in human cancers

Ying Wu 1, 2, *, , Yanshen Hou 3, *, , Peng Xu 2, , Yujiao Deng 1, 2, , Kang Liu 4, , Meng Wang 2, , Tian Tian 2, , Cong Dai 2, , Na Li 1, 2, , Qian Hao 2, , Dingli Song 2, , Ling hui Zhou 1, 2, , Zhijun Dai 1, 2, ,

  • 1 Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
  • 2 Department of Oncology, The 2nd Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
  • 3 Department of Anesthesiology, The 3rd Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Tumor Hospital), Urumqi, Xinjiang, China
  • 4 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
* Equal contribution

received: July 18, 2019 ; accepted: October 5, 2019 ; published: October 15, 2019 ;
How to Cite

Copyright © 2019 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: As an important downstream factor in the Hippo pathway, yes-associated protein 1(YAP1) has been detected to be elevated in various cancers and demonstrated to play a role in tumor development. Therefore, we evaluated by a meta-analysis the prognostic value of YAP1 in cancer patients.

Results: Sixty-eight studies with 8631 patients were identified. The results indicated that YAP1 overexpression predicted unfavorable patient prognosis in studies with overall survival (OS) (HR=1.76, 95%CI: 1.50-2.06, p<0.001) and disease-free survival (DFS) (HR=1.39, 95%CI: 1.22-1.59, p<0.001), as well as in studies with recurrence-free survival (RFS) (HR=2.38, 95%CI: 1.73-3.27, p<0.001), and disease-specific survival (DSS) (HR=2.04, 95%CI: 1.55-2.70, p<0.001). Meanwhile, YAP1 overexpression was also observed to be significantly associated with worse OS in GEPIA (HR=1.2, p<0.001).

Conclusions: Overexpression of YAP1 showed great association with poorer prognosis in patients with various cancers, particularly liver cancer. Therefore, YAP1 might be an important prognostic marker and a novel target of cancer therapy.

Methods: We searched for potential publications in several online databases and retrieved relevant data. Overall and subgroup analyses were performed. Begg’s and Egger’s tests were used to assess publication bias. Online dataset GEPIA was used to generate the survival curves and verify the prognostic role of YAP1 in patients with tumors.


CI: confidence interval; DFS: disease-free survival; DSS: disease-specific survival; HR: hazard ratio; IHC: immunohistochemistry; NOS: Newcastle-Ottawa Scale; OS: overall survival; PCR: polymerase chain reaction; PFS: progression-free survival; RFS: recurrence-free survival; YAP1: yes-associated protein 1.